Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
|ClinicalTrials.gov Identifier: NCT00627354|
Recruitment Status : Completed
First Posted : March 3, 2008
Last Update Posted : May 16, 2011
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, etoposide, and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which drug is more effective in killing tumor cells.
PURPOSE: This randomized phase II trial is studying how well mitoxantrone works compared to etoposide or vinorelbine works as second-line therapy in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: etoposide Drug: mitoxantrone hydrochloride Drug: prednisone Drug: vinorelbine tartrate||Phase 2|
- Determine the palliative response rate in patients with hormone-resistant prostate cancer treated with mitoxantrone hydrochloride vs etoposide vs vinorelbine ditartrate as second-line therapy.
- Determine the duration of palliative response in patients treated with these regimens.
- Determine the biological response (PSA > 50%) in these patients.
- Determine the time to progression (biological and clinical) in these patients.
- Determine the overall survival of these patients.
- Determine the quality of life and the impact on autonomy of patients over 70 years of age.
- Determine the toxicity of these regimens in these patients.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive mitoxantrone hydrochloride IV over 5 minutes once a week for 3 weeks.
- Arm II: Patients receive oral etoposide twice daily on days 1-14.
- Arm III: Patients receive oral vinorelbine ditartrate once daily on days 1 and 8 and oral prednisone once daily on days 1-21.
Treatment in all three arms repeats every 3 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Official Title:||Phase 2 Randomized Study Evaluating 3 Chemotherapy Regimens as Second-line Treatment in Patients With Hormone-refractory Metastatic Prostate Cancer|
|Study Start Date :||September 2006|
|Primary Completion Date :||May 2011|
- Palliative response rate
- Duration of palliative response
- Biological response
- Tumor response as assessed by RECIST criteria
- Time to progression
- Overall survival
- Quality of life as assessed by QLQ-PR25
- Impact on autonomy in patients > 70 years of age
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00627354
|Centre Regional Francois Baclesse|
|Caen, France, 14076|
|Study Chair:||Florence Joly, MD, PhD||Centre Francois Baclesse|